296 related articles for article (PubMed ID: 18350479)
1. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
[TBL] [Abstract][Full Text] [Related]
2. The relationship of the interleukin-6 -174 G>C gene polymorphism with cardiovascular risk factors in Turkish polycystic ovary syndrome patients.
Erdogan M; Karadeniz M; Berdeli A; Tamsel S; Yilmaz C
Int J Immunogenet; 2009 Oct; 36(5):283-8. PubMed ID: 19744034
[TBL] [Abstract][Full Text] [Related]
3. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
5. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
6. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
[TBL] [Abstract][Full Text] [Related]
7. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome.
Luque-Ramírez M; Mendieta-Azcona C; Alvarez-Blasco F; Escobar-Morreale HF
Hum Reprod; 2007 Dec; 22(12):3197-203. PubMed ID: 17933750
[TBL] [Abstract][Full Text] [Related]
8. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
9. Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors.
Kaya C; Pabuccu R; Berker B; Satiroglu H
Fertil Steril; 2010 Mar; 93(4):1200-7. PubMed ID: 19131059
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
11. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ersoy R; Karakoç A; Yetkin I; Ayvaz G; Cakir N; Arslan M
Hum Reprod; 2005 Sep; 20(9):2414-20. PubMed ID: 15890734
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome.
Bahceci M; Aydemir M; Tuzcu A
Fertil Steril; 2007 Jun; 87(6):1363-8. PubMed ID: 17362944
[TBL] [Abstract][Full Text] [Related]
13. Endothelial dysfunction in PCOS: role of obesity and adipose hormones.
Carmina E; Orio F; Palomba S; Longo RA; Cascella T; Colao A; Lombardi G; Rini GB; Lobo RA
Am J Med; 2006 Apr; 119(4):356.e1-6. PubMed ID: 16564785
[TBL] [Abstract][Full Text] [Related]
14. Retinol-binding protein in nonobese women with polycystic ovary syndrome.
Lee JW; Im JA; Lee DC; Lee HR; Shim JY
Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278
[TBL] [Abstract][Full Text] [Related]
15. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Adali E; Yildizhan R; Kurdoglu M; Bugdayci G; Kolusari A; Sahin HG
Fertil Steril; 2010 Jul; 94(2):666-72. PubMed ID: 19368913
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk factors in polycystic ovary syndrome.
Karaer A; Cavkaytar S; Mert I; Buyukkagnici U; Batioglu S
J Obstet Gynaecol; 2010 May; 30(4):387-92. PubMed ID: 20455724
[TBL] [Abstract][Full Text] [Related]
18. Association of polycystic ovary syndrome with cardiovascular risk factors.
Akram T; Hasan S; Imran M; Karim A; Arslan M
Gynecol Endocrinol; 2010 Jan; 26(1):47-53. PubMed ID: 19639500
[TBL] [Abstract][Full Text] [Related]
19. Low-grade chronic inflammation is not accompanied by structural arterial injury in polycystic ovary syndrome.
Costa LO; dos Santos MP; Oliveira M; Viana A
Diabetes Res Clin Pract; 2008 Aug; 81(2):179-83. PubMed ID: 18499295
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Piperi C; Kalofoutis A; Creatsas G
Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
